DHAalso reduced the expression of the molecular mediators of SLE inflammation,namely TLR4/IRF3/IFN-β, in a dose-dependent manner in a concentrationrange from 0.1 μM to 10 μM. Recently, also a formulation comprising DHA co-delivered with HGMB1siRNA in a PEG liposome functionalized with a cell-penetrating peptidewas tested in vitro as anti-SLE treatment. The gene discussed is TLR4; the disease is systemic lupus erythematosus.